| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378890 | Bioorganic & Medicinal Chemistry Letters | 2006 | 5 Pages |
Abstract
A series of 2,3-diaminopyridine bradykinin B1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B1 receptor.
Graphical abstractA series of 2,3-diaminopyridine bradykinin B1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B1 receptor.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Scott D. Kuduk, Christina Ng Di Marco, Ronald K. Chang, Michael R. Wood, June J. Kim, Kathy M. Schirripa, Kathy L. Murphy, Richard W. Ransom, Cuyue Tang, Maricel Torrent, Sookhee Ha, Thomayant Prueksaritanont, Douglas J. Pettibone, Mark G. Bock,